The management of unruptured intracranial aneurysms (UIA) is challenging. The current risk evaluation based on traditional risk factors including size, location, irregular shape etc. has limited sensitivity and specificity. For example, more than half of ruptured intracranial aneurysms are smaller than the treatment threshold of 7mm. Therefore, finding more accurate biomarkers for UIA stability is urgently needed to improve patient management.

中文翻译：

---

壁增强作为颅内动脉瘤稳定性的新兴标志物：通往临床试验潜在目标的路线图

未破裂颅内动脉瘤 (UIA) 的管理具有挑战性。目前基于大小、位置、不规则形状等传统风险因素的风险评估敏感性和特异性有限。例如，超过一半的破裂颅内动脉瘤小于7mm的治疗阈值。因此，迫切需要寻找更准确的 UIA 稳定性生物标志物以改善患者管理。